budesonide inhalation suspension / Generic mfg. |
| Completed | 2 | 32 | US | MAP0010 low dose, MAP0010 high dose, Budesonide inhalation suspension 0.25mg, Pulmicort Respules®, Budesonide inhalation suspension 0.5mg | Allergan, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan | Asthma | 01/08 | 03/08 | | |
NCT01814618: Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery |
|
|
| Withdrawn | 2 | 0 | US | Budesonide Respules, Pulmicort respules | University of North Carolina, Chapel Hill | Olfaction Disorders, Sinusitis, Paranasal Sinus Diseases | 11/13 | 11/13 | | |
2006-004035-30: A Randomised, Single Dose Exposure Study to Assess the Safety, Tolerability and Pharmacokinetics of Investigational Captisol-Enabled® Budesonide InhalationSolution (CBIS) Delivered via eFlow® Nebuliser and Conventional BudesonideInhalation Suspension (Pulmicort Respules®) Delivered via LC Plus® JetNebuliser in Children with Asthma |
|
|
| Ongoing | 2 | 18 | Europe | Captisol-Enabled Budesonide, Pulmicort 250 Respules, CBIS, Pulmicort 250 Respules, Pulmicort 250 Respules | Verus Pharmaceuticals Inc | Asthma | | | | |
2007-001968-78: A Phase II, Randomised, Double-Blind, Placebo-Controlled Pilot Efficacy Study of ADC4022 (Theophylline Solution for Inhalation) on Markers of Pulmonary Inflammation in Subjects with Moderate to Severe COPD |
|
|
| Ongoing | 2 | 65 | Europe | ADC4022, Pulmicort Respules, ADC4022, Budesonide, Pulmicort Respules 1 mg Nebuliser Suspension, Pulmicort Respules 1 mg Nebuliser Suspension | Argenta Discovery Ltd. | Chronic Obstructive Pulmonary Disease (COPD) | | | | |
BOREAS, NCT04933383: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics |
|
|
| Completed | 1/2 | 23 | Europe | AQ001S 0.125 mg/ml, budesonide inhalation solution 0.125 mg/ml, Budesonide 0.125 mg/ml inhalation suspension, Budesonide inhalation suspension 0.125 mg/ml | Aquilon Pharmaceuticals S.A. | Asthma | 12/22 | 01/23 | | |